ROIVANT SCIENCES LTD. Debt Securities Available For Sale Excluding Accrued Interest
ROIVANT SCIENCES LTD. (ROIV) had Debt Securities Available For Sale Excluding Accrued Interest of $2.59 billion as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets
us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest · last filed 2026-08-06
- 2026-06-30: Debt Securities Available For Sale Excluding Accrued Interest $2.59B.
- 2026-03-31: Debt Securities Available For Sale Excluding Accrued Interest $2.87B.
- 2025-03-31: Debt Securities Available For Sale Excluding Accrued Interest $2.17B.
| Period end | Debt Securities Available For Sale Excluding Accrued Interest |
|---|---|
| 2026-06-30 | $2.59B 10-Q · filed 2026-08-06 |
| 2026-03-31 | $2.87B 10-Q · filed 2026-08-06 |
| 2025-03-31 | $2.17B 10-K · filed 2026-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |